Insulet Co. (NASDAQ:PODD) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Insulet Co. (NASDAQ:PODD) has been assigned an average recommendation of “Moderate Buy” from the eighteen ratings firms that are presently covering the stock, Marketbeat reports. Three equities research analysts have rated the stock with a hold rating and fifteen have issued a buy rating on the company. The average 1 year target price among analysts that have covered the stock in the last year is $239.18.

A number of equities research analysts have issued reports on PODD shares. Wolfe Research raised Insulet from a “peer perform” rating to an “outperform” rating and set a $200.00 target price for the company in a research report on Tuesday, May 7th. Canaccord Genuity Group increased their price objective on Insulet from $226.00 to $234.00 and gave the company a “buy” rating in a research report on Friday, May 10th. OTR Global reissued a “mixed” rating on shares of Insulet in a research report on Monday, June 10th. Redburn Atlantic initiated coverage on Insulet in a research report on Thursday, May 30th. They issued a “buy” rating and a $235.00 price objective for the company. Finally, Barclays reduced their price objective on Insulet from $213.00 to $200.00 and set an “equal weight” rating for the company in a research report on Monday, May 13th.

Insider Activity

In other news, Director Timothy J. Scannell sold 3,300 shares of the firm’s stock in a transaction on Tuesday, May 28th. The stock was sold at an average price of $180.90, for a total value of $596,970.00. Following the completion of the sale, the director now directly owns 42,586 shares in the company, valued at $7,703,807.40. The sale was disclosed in a filing with the SEC, which is accessible through this link. In related news, Director Timothy J. Scannell sold 7,000 shares of the firm’s stock in a transaction dated Monday, June 10th. The stock was sold at an average price of $190.51, for a total value of $1,333,570.00. Following the transaction, the director now owns 35,586 shares in the company, valued at $6,779,488.86. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Timothy J. Scannell sold 3,300 shares of the firm’s stock in a transaction dated Tuesday, May 28th. The shares were sold at an average price of $180.90, for a total value of $596,970.00. Following the completion of the transaction, the director now owns 42,586 shares in the company, valued at approximately $7,703,807.40. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 13,931 shares of company stock worth $2,636,286. 0.47% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Insulet

Several hedge funds have recently added to or reduced their stakes in the company. Capital Research Global Investors boosted its holdings in Insulet by 19.7% in the fourth quarter. Capital Research Global Investors now owns 9,476,623 shares of the medical instruments supplier’s stock valued at $2,056,255,000 after acquiring an additional 1,556,455 shares during the last quarter. Vanguard Group Inc. lifted its holdings in shares of Insulet by 2.1% during the 1st quarter. Vanguard Group Inc. now owns 8,199,114 shares of the medical instruments supplier’s stock valued at $1,405,328,000 after purchasing an additional 169,506 shares in the last quarter. Baillie Gifford & Co. lifted its holdings in shares of Insulet by 18.9% during the 1st quarter. Baillie Gifford & Co. now owns 1,442,279 shares of the medical instruments supplier’s stock valued at $247,207,000 after purchasing an additional 229,520 shares in the last quarter. Norges Bank bought a new position in shares of Insulet during the 4th quarter valued at about $227,655,000. Finally, William Blair Investment Management LLC lifted its holdings in shares of Insulet by 3.7% during the 1st quarter. William Blair Investment Management LLC now owns 952,268 shares of the medical instruments supplier’s stock valued at $163,219,000 after purchasing an additional 33,579 shares in the last quarter.

Insulet Price Performance

Shares of PODD opened at $206.81 on Thursday. The company has a market capitalization of $14.48 billion, a price-to-earnings ratio of 62.67, a P/E/G ratio of 3.70 and a beta of 1.14. Insulet has a fifty-two week low of $125.82 and a fifty-two week high of $298.95. The company has a debt-to-equity ratio of 1.72, a current ratio of 3.74 and a quick ratio of 2.75. The business’s 50-day moving average is $182.04 and its 200-day moving average is $186.36.

Insulet (NASDAQ:PODD) last issued its earnings results on Thursday, May 9th. The medical instruments supplier reported $0.73 earnings per share for the quarter, beating analysts’ consensus estimates of $0.39 by $0.34. Insulet had a return on equity of 34.06% and a net margin of 13.14%. The company had revenue of $441.70 million for the quarter, compared to the consensus estimate of $424.05 million. During the same quarter in the prior year, the company earned $0.23 EPS. The firm’s quarterly revenue was up 23.3% on a year-over-year basis. Equities research analysts expect that Insulet will post 3.11 EPS for the current fiscal year.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.